跳至主要内容
临床试验/NCT05402930
NCT05402930招募中不适用

Usefulness of Angiomammography for Predicting the Response to Neoadjuvant Chemotherapy in Breast Cancer

CHU de Quebec-Universite Laval1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年1月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography

研究概览

简要总结

The best prognostic factor following neoadjuvant chemotherapy is the pathological complete response (pCR). pCR is defined as the absence of invading cells in the breast and lymph nodes following neoadjuvant chemotherapy treatment. Since patients with pCR have a better prognosis than those without pCR, some studies have evaluated different methods to predict pCR early in treatment. Thus, patients who do not respond optimally to treatment could be identified early and changed treatment in order to maximize the chances of pCR and avoid the morbidity of poorly effective treatments. To do this, several modalities have been proposed, including MRI, mammography, ultrasound, positron emission tomography, elastography, and serial biopsies, but these techniques have shown predictive and sometimes expensive. Nevertheless, assessment of tumor response after cycle 2 has been suggested to be appropriate for the prediction of pCR.

The main objective of this study is to compare the performance of two diagnostic modalities, namely CESM and MRI, in the evaluation of the response of a malignant breast tumor to neoadjuvant chemotherapy and the prediction of pCR. The radiological response will also be compared to the clinical response.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Female aged 18 and over
  • •Histologically proven breast cancer by large gauge needle
  • •No evidence of distant metastasis
  • •Neoadjuvant chemotherapy with or without concomitant targeted therapy
  • •Breast tumor initially measurable by clinical examination

排除标准

  • •Refusal to perform the biopsy or surgery
  • •Pregnant or possibly pregnant woman
  • •Usual contraindication to contrast product
  • •Significant kidney failure
  • •Allergy to contrast medium
  • •frank hyperthyroidism
  • •Usual contraindications to MRI

研究组 & 干预措施

Neoadjuvant chemotherapy

Experimental

干预措施: Angiomammography (Diagnostic Test)

结局指标

主要结局

Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography

时间窗: Cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Prediction of pCR using angiomammography after cycle 2 of neoadjuvant chemotherapy, based on a 50% reduction in lesion size at angiomammography

次要结局

未报告次要终点

研究者

发起方
CHU de Quebec-Universite Laval
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Angiomammography and Neoadjuvant Chemotherapy | 临床试验